CClinicalTrials.gg
CompletedNCT06961305AL-MEDUpdated May 6, 2026

A Post-Marketing Study of Alexa Medium for Сorrection of the Lips Volume Loss

An interventional study of Cross-linked Hyaluronic Acid Gel in Lip Volume Enhancement, Lip Augmentation and Aesthetic, sponsored by Institute Hyalual GmbH. Completed at 4 sites in 2 countries. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Institute Hyalual GmbH · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Aug 2021, registered Apr 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
25 Years to 70 Years
Sex
All
01

Study summary

This post-marketing, prospective, multicentre, single-arm, open-label clinical investigation aimed to evaluate the safety, tolerability, and effectiveness of the injectable medical device Alexa Medium (based on cross-linked hyaluronic acid) for the correction of lip volume loss. Participants received one or two injections of the product, and effectiveness was assessed using the Global Aesthetic Improvement Scale (GAIS) and the Medicis Lip Fullness Scale (MLFS). Safety data were collected at each visit. The study demonstrated high effectiveness and safety, with most subjects achieving their personal aesthetic goals.

02

Conditions studied

  • Lip Volume Enhancement
  • Lip Augmentation
  • Aesthetic

Keywords

  • Aesthetic
  • Lip Volume
  • Alexa Medium
03

In context

Lead sponsor

Institute Hyalual GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subject's age 25 to 70.
  • Subject will receive an injection of the medical device 'Alexa Medium' manufactured by Diaco Biofarmaceutici S.r.l., Italy for correction of the lips volume loss within accepted cosmetological practice.
  • Subject's lips requiring correction of the lips volume loss according to the Investigator's judgement.
  • The subject has established a realistic aesthetic improvement goal that the Investigator agrees is achievable, i.e., have realistic expectations of aesthetic results.
  • Subject willing to have photographs of the face taken.
  • Subject psychologically able to understand the Investigation related information and to give a written informed consent.
  • Subject able and agreeing to follow Investigation procedures, instructions and likely to complete all required visits.
  • The subject agreed to participate in the Investigation and signed the Informed Consent Form.

Exclusion criteria

Exclusion Criteria:

  • Subject's age less than 25 or more than 70.
  • Subject tends to develop hypertrophic scarring.
  • Subjects has known hypersensitivity to cross-linked hyaluronic acid.
  • Subjects has history of severe and/or multiple allergies.
  • Subjects has history of herpetic rash.
  • Subject has impaired haemostatic function.
  • Subject is on anticoagulant medication(s) or is using substances that can prolong bleeding.
  • Subject has present or past history of autoimmune disease or autoimmune deficiency.
  • Subject is undergoing immunosuppressive therapy.
  • Subject has acute rheumatic fever with heart complications.
  • Subject has tumour in area of the IMD application.
  • Subject has active tuberculosis.
  • Subject with presence of any other chronic disease that in the opinion of the Investigator may interfere with the outcome of the Investigation.
  • Subject is a pregnant or breastfeeding women.
  • Subject is presenting with cutaneous inflammatory and/or infectious diseases (acne, herpes, etc.) in area of the IMD application.
  • Subject plans laser correction, deep chemical peels or dermabrasion during the potential participation in this Investigation.
  • Subject has undergone recently laser correction, deep chemical peels, dermabrasion or surface peels, so the inflammatory reaction from the peel is significant.
  • Subject has a permanent implant in the area of the IMD application.
  • Subject has already injected more than 18 mL of dermal fillers per 60 kg of body mass per year.
  • Subject refuses or is suspected of inability to comply with the requirements of the CIP.
  • Subject has difficulty understanding the language in which the informed consent is written.
  • Any other reason that the Investigator believes prevents the subject from participating in the Investigation (including suspicion of body dysmorphic disorder).
  • Subject takes part in the other Investigation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Single Arm: Alexa Medium

    Participants received one or two injections of Alexa Medium, a cross-linked hyaluronic acid gel, into the mucous membrane of the lips for aesthetic correction of lip volume loss. The second injection was optional and performed at the discretion of the investigator during the second visit.

    Device: Cross-linked Hyaluronic Acid Gel

Interventions

  • DeviceCross-linked Hyaluronic Acid Gel

    This intervention involves the injection of Alexa Medium, a sterile, cross-linked hyaluronic acid gel (17.5 mg/mL). The gel is administered into the mucous membrane of the lips for aesthetic restoration of lip volume loss. The product is supplied in a pre-filled 1 mL syringe and injected by a trained medical professional. One or two injections were administered per participant, with the second injection performed at the investigator's discretion at Visit 2. The device is manufactured by Diaco Biofarmaceutici S.r.l., Italy.

06

What researchers measure

Primary outcomes

  1. Global Aesthetic Improvement Scale (GAIS) Score at Day 60

    Change in GAIS score from baseline to Day 60, as evaluated by the Investigator. GAIS is a 5-point scale ranging from 1 (exceptional improvement) to 5 (worsened patient).

    Time frame: Day 60 ±5 days

  2. Medicis Lip Fullness Scale (MLFS) Score at Day 60

    hange in MLFS score from baseline to Day 60, as evaluated by the Investigator. MLFS is a 5-grade scale (1=very thin lips, 5=very full lips)

    Time frame: Day 60 ±5 days

07

Study locations

4 sites
  • Provita Sp. z o.o.
    Katowice, 40-611, Poland
  • Ośrodek medyczny OSTEOMED s.c.
    Krakow, 30-074, Poland
  • Ostrowieckie Centrum Medyczne
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Institute Hyalual LLC
    Kyiv, 03151, Ukraine
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961305
Lead sponsor
Institute Hyalual GmbH
Responsible party
Sponsor
First posted
May 7, 2025
Start date
Aug 10, 2021
Primary completion
Jun 2, 2022
Completion
Jun 2, 2022
Last update
May 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion